Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales

Overview

• US pharmaceutical firm's fiscal Q4 revenue rose 6.4%, beating analyst expectations

• Company reported near break-even net loss for the quarter, improving from prior year

Outlook

• Company expects EXXUA launch momentum to continue, with evolving prescribing and payer patterns

• Company aims to build toward more consistent positive adjusted EBITDA levels during fiscal 2027

• ADHD and Pediatric portfolios expected to provide financial stability to support EXXUA investment

Result Drivers

• EXXUA LAUNCH - Q4 revenue was driven by the first full quarter of EXXUA sales, with management citing growing prescription volume and broadening adoption

• ADHD PORTFOLIO - Sequential improvement in ADHD Portfolio revenue was attributed to higher units, improved gross-to-net economics, and stable performance across existing brands, despite generic competition

• PEDIATRIC PORTFOLIO - Q4 Pediatric Portfolio revenue increased from the prior quarter as product availability normalized following a supply disruption

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Aytu Biopharma Inc is $7.00, about 229.4% above its September 21 closing price of $2.13

Reuters Recommended Reads

• Sept 21 - AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties

• Sept 22 - Amgen's autoimmune drug succeeds in late-stage trial

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)